Page 174 - EJMO-9-2

Eurasian Journal of
Medicine and Oncology Genetic insights into CAD drug targets

doi: 10.1097/CRD.0000000000000428 OMICS. 2012;16(5):284-287.
8. Oikonomou E, Siasos G, Tsigkou V, et al. Coronary doi: 10.1089/omi.2011.0118
artery disease and endothelial dysfunction: Novel 19. Otasek D, Morris JH, Boucas J, Pico AR, Demchak B.
diagnostic and therapeutic approaches. Curr Med Chem. Cytoscape automation: Empowering workflow-based
2020;27(7):1052-1080.
network analysis. Genome Biol. 2019;20(1):185.
doi: 10.2174/0929867326666190830103219
doi: 10.1186/s13059-019-1758-4
9. Serruys PW, Ono M, Garg S, et al. Percutaneous coronary 20. Yoo M, Shin J, Kim J, et al. DSigDB: Drug signatures database
revascularization: JACC historical breakthroughs in for gene set analysis. Bioinformatics. 2015;31(18):3069-3071.
perspective. J Am Coll Cardiol. 2021;78(4):384-407.
doi: 10.1093/bioinformatics/btv313
doi: 10.1016/j.jacc.2021.05.024
21. Shaffer JM, Smithgall TE. Promoter methylation blocks FES
10. Grover MP, Ballouz S, Mohanasundaram KA, et al. Novel protein-tyrosine kinase gene expression in colorectal cancer.
therapeutics for coronary artery disease from genome- Genes Chromosomes Cancer. 2009;48(3):272-284.
wide association study data. BMC Med Genomics.
2015;8 Suppl 2(Suppl 2):S1. doi: 10.1002/gcc.20638
doi: 10.1186/1755-8794-8-S2-S1 22. Li J, Smithgall TE. Fibroblast transformation by Fps/Fes
tyrosine kinases requires Ras, Rac, and Cdc42 and induces
11. Hughes MF, Lenighan YM, Godson C, Roche HM. Exploring extracellular signal-regulated and c-Jun N-terminal kinase
coronary artery disease GWAs targets with functional links activation. J Biol Chem. 1998;273(22):13828-13834.
to immunometabolism. Front Cardiovasc Med. 2018;5:148.
doi: 10.1074/jbc.273.22.13828
doi: 10.3389/fcvm.2018.00148
23. Laurent CE, Smithgall TE. The c-Fes tyrosine kinase
12. Storm CS, Kia DA, Almramhi MM, et al. Finding cooperates with the breakpoint cluster region protein (Bcr)
genetically-supported drug targets for Parkinson’s disease to induce neurite extension in a Rac- and Cdc42-dependent
using Mendelian randomization of the druggable genome. manner. Exp Cell Res. 2004;299(1):188-198.
Nat Commun. 2021;12(1):7342.
doi: 10.1016/j.yexcr.2004.05.010
doi: 10.1038/s41467-021-26280-1
24. Chen Y, Yang Z, Meng M, et al. Cullin mediates degradation
13. Finan C, Gaulton A, Kruger FA, et al. The druggable genome of RhoA through evolutionarily conserved BTB adaptors to
and support for target identification and validation in drug control actin cytoskeleton structure and cell movement. Mol
development. Sci Transl Med. 2017;9(383):eaag1166.
Cell. 2009;35(6):841-855.
doi: 10.1126/scitranslmed.aag1166
doi: 10.1016/j.molcel.2009.09.004
14. Hemani G, Zheng J, Elsworth B, et al. The MR-Base platform 25. Karamanavi E, McVey DG, van der Laan SW, et al. The FES
supports systematic causal inference across the human Gene at the 15q26 coronary-artery-disease locus inhibits
phenome. Elife. 2018;7:e34408.
atherosclerosis. Circ Res. 2022;131(12):1004-1017.
doi: 10.7554/eLife.34408
doi: 10.1161/CIRCRESAHA.122.321146
15. Greco MF, Minelli C, Sheehan NA, Thompson JR. 26. Antcliff A, McCullough LD, Tsvetkov AS. G-Quadruplexes
Detecting pleiotropy in Mendelian randomisation studies and the DNA/RNA helicase DHX36 in health, disease, and
with summary data and a continuous outcome. Stat Med. aging. Aging (Albany NY). 2021;13(23):25578-25587.
2015;34(21):2926-2940.
doi: 10.18632/aging.203738
doi: 10.1002/sim.6522
27. Zeng Y, Qin T, Flamini V, et al. Identification of DHX36 as a
16. Giambartolomei C, Vukcevic D, Schadt EE, et al. tumour suppressor through modulating the activities of the
Bayesian test for colocalisation between pairs of genetic stress-associated proteins and cyclin-dependent kinases in
association studies using summary statistics. PLoS Genet. breast cancer. Am J Cancer Res. 2020;10(12):4211-4233.
2014;10(5):e1004383.
28. Lai JC, Ponti S, Pan D, et al. The DEAH-box helicase RHAU
doi: 10.1371/journal.pgen.1004383
is an essential gene and critical for mouse hematopoiesis.
17. Wang Q, Dhindsa RS, Carss K, et al. Rare variant contribution Blood. 2012;119(18):4291-4300.
to human disease in 281,104 UK Biobank exomes. Nature. doi: 10.1182/blood-2011-08-362954
2021;597(7877):527-532.
29. Nikpay M, Soubeyrand S, Tahmasbi R, McPherson R.
doi: 10.1038/s41586-021-03855-y
Multiomics screening identifies molecular biomarkers
18. Yu G, Wang LG, Han Y, He QY. clusterProfiler: An R package causally associated with the risk of coronary artery disease.
for comparing biological themes among gene clusters. Circ Genom Precis Med. 2020;13(6):e002876.

Volume 9 Issue 2 (2025) 166 doi: 10.36922/ejmo.7387